Whole-Virion Inactivated SARS-CoV-2 Vaccine
Whole-Virion Inactivated SARS-CoV-2 Vaccine Uses, Dosage, Side Effects, Food Interaction and all others data.
Whole-Virion Inactivated SARS-CoV-2 Vaccine is a vaccine candidate created by the Indian Council of Medical Research (ICMR). The candidate, a whole virion inactivated SARS-CoV-2 vaccine, was developed from a well-known SARS-CoV-2 strain and a vero cell platform (CCL-81) with adjuncts of either aluminum hydroxide gel (Algel) or a novel TLR7/8 agonist adsorbed gel. The components of the vaccine include Whole-Virion Inactivated SARS-CoV-2 VaccineA, Whole-Virion Inactivated SARS-CoV-2 VaccineB, and Whole-Virion Inactivated SARS-CoV-2 VaccineC. Animal studies in mice, rats, and rabbits reported Whole-Virion Inactivated SARS-CoV-2 Vaccine immunogenicity at two separate antigen concentrations with both types of adjuvants. The formulation with the TLR7/8 adjuvant specifically induced significant Th1 biased antibody responses and increased SARS-CoV-2 lymphocyte responses. Thus, as of July 2020, Whole-Virion Inactivated SARS-CoV-2 Vaccine is in Phase 1/2 clinical trials assessing safety and immunogenicity in humans (NCT04471519).
| Trade Name | Whole-Virion Inactivated SARS-CoV-2 Vaccine |
| Generic | BBV152 |
| BBV152 Other Names | BBV-152, Covaxin, Whole-Virion Inactivated SARS-CoV-2 Vaccine |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | September 19, 2023 at 7:00 am |
Innovators Monograph
You find simplified version here Whole-Virion Inactivated SARS-CoV-2 Vaccine
